Novan Therapeutics' Abstract Accepted for Poster Session at 2014 Society for Investigative Dermatology Annual Meeting
April 23, 2014
Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced that data from the Phase 2 clinical trial in acne vulgaris with its lead product candidate, SB204, has been accepted for presentation at the 2014 Annual Meeting of the Society for Investigative Dermatology (SID) May 7-10, 2014 at the Albuquerque Convention Center in Albuquerque, New Mexico.
March 21, 2014
Durham, NC – Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris.
December 12, 2013
Durham, NC – Novan Therapeutics announced today that the Company has been selected to present at the inaugural Dermatology Summit in San Francisco on January 12, 2014.
August 26, 2013
DURHAM, N.C. – Novan Therapeutics announced today that the U.S. Department of Health and Human Services has entered into a contract with Novan to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns.